Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect Maravai LifeSciences to post earnings of ($0.03) per share for the quarter. Maravai LifeSciences has set its FY 2024 guidance at EPS.Individual interested in registering for the company's earnings conference call can do so using this link.
Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $74.14 million during the quarter, compared to the consensus estimate of $62.99 million. Maravai LifeSciences had a negative return on equity of 1.31% and a negative net margin of 41.19%. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Maravai LifeSciences Stock Performance
MRVI traded up $0.22 during trading on Wednesday, hitting $8.42. The stock had a trading volume of 1,479,073 shares, compared to its average volume of 2,520,425. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $16.62. The company has a debt-to-equity ratio of 0.70, a quick ratio of 7.41 and a current ratio of 8.00. The company has a 50 day simple moving average of $7.89 and a 200-day simple moving average of $6.66.
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Stifel Nicolaus dropped their target price on shares of Maravai LifeSciences from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, February 23rd. Craig Hallum assumed coverage on shares of Maravai LifeSciences in a report on Wednesday, April 10th. They set a "buy" rating and a $15.00 price objective on the stock. Finally, Royal Bank of Canada boosted their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an "outperform" rating in a report on Friday, February 23rd. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $11.56.
Read Our Latest Stock Report on MRVI
About Maravai LifeSciences
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
